Lentiviral vectors for in vivo targeting of hematopoietic cells

The present application, in some embodiments, is directed to a synthetic polynucleotide including a nucleic acid sequence encoding a mutated vesicular stomatitis virus G (VSV-G) protein, being characterized by having reduced or no binding affinity to a low-density lipoprotein (LDL) receptor, compare...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Noam DIAMANT, Einat NISSIM-ELIRAZ, Liron ELKOUBY
Format:	Patent
Sprache:	eng ; heb
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present application, in some embodiments, is directed to a synthetic polynucleotide including a nucleic acid sequence encoding a mutated vesicular stomatitis virus G (VSV-G) protein, being characterized by having reduced or no binding affinity to a low-density lipoprotein (LDL) receptor, compared to a control VSV-G. Further provided is a viral vector including the mutated VSV-G protein, and optionally further includes a single-chain variable fragment (scFv). Further provided are, inter alia, compositions including the expression vector, and use thereof, such as for in vivo gene therapy in a subject in need thereof.